Absci Corp employs a proprietary Integrated Drug Creation platform combining AI and automation to expedite biologic drug discovery, focusing on underexplored targets with high unmet need. Since commercial operations began in 2018, growth has been driven primarily by partnerships rather than product sales, leading to revenues plateauing below $6 million annually amid increasing R&D expenses. The lead candidate ABS-201 is advancing through Phase 1/2a trials for androgenetic alopecia with interim data expected in H2 2026, alongside plans for a Phase 2 trial in endometriosis. Absci faces significant operating losses exceeding $115 million in 2025, heavy cash burn, and absence of royalties from licensed products, underscoring challenges in translating platform innovation into sustainable profitability. Critical upcoming milestones center on clinical readouts and partner engagements that could validate the platform’s commercial potential.